Cover Image

4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells.

Saved in:

Bibliographic Details
Main Authors:	J. Jacobson (Author), B. Sleebs (Author), K. Jarman (Author), W. Nguyen (Author), T. Mota (Author), L. Harty (Author), G. Khoury (Author), N. Tay (Author), P. Cameron (Author), S. Lewin (Author), D.F.J. Purcell (Author)
Format:	Book
Published:	Elsevier, 2017-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

37 Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1
by: M. Lee, et al.
Published: (2016)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Synergise or perish
by: Harpreet Singh Grover
Published: (2021)

PP 1.36 - 00182 Effect of HIV-1C Transmitted/Founder Viruses 5'LTRand tat Genetic Variation on Viral Reservoir Size and Latency Reversal Potential
by: Shreyal Maikoo, et al.
Published: (2022)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
by: H. Lu, et al.
Published: (2016)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019)

An HIV-Tat inducible mouse model system of childhood HIV-associated nephropathy
by: Pingtao Tang, et al.
Published: (2020)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

OP 8.2 - 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection
by: M. Freeman, et al.
Published: (2022)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial
by: J. Alagaratnam, et al.
Published: (2019)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015)

Validation of an unbiased screen method for the identification of secondary fungal metabolites reversing HIV-1 latency
by: M. Stoszko, et al.
Published: (2017)

The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial
by: J. Symons, et al.
Published: (2017)

Multiple NF-κB elements in the LTR of HIV-1 subtype C coordinate with the auto-regulatory circuit of Tat to drive rapid establishment of latency
by: S. Chakraborty, et al.
Published: (2017)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

Suppression of the HIV-1 reservoir with a potent Tat inhibitor
by: S. Valente, et al.
Published: (2015)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency
by: Emade Nkwelle C, et al.
Published: (2024)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

Molecular characterisation of the inhibitor didehydro-Cortistatin A with the HIV-1 Tat protein
by: S. Mediouni, et al.
Published: (2017)

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment
by: Xu-Sheng Huang, et al.
Published: (2022)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023)

Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity
by: Jean-Pierre Louboutin, et al.
Published: (2014)